Drug data last refreshed 5h ago · AI intelligence enriched 8h ago
SUTAB is an oral tablet formulation of sodium sulfate, magnesium sulfate, and potassium chloride used as a bowel preparation agent prior to colonoscopy or other gastrointestinal procedures. It works by osmotically drawing fluid into the intestinal lumen to cleanse the colon. This electrolyte-based formulation represents a solid-dose alternative to liquid polyethylene glycol solutions.
Product is in peak commercialization phase with $29M in Part D spending; teams are likely focused on market penetration and maintaining share against established bowel prep competitors.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
SUTAB offers career opportunities in a stable, peak-stage commercial product with 11+ years of patent protection, providing long-term job security and growth potential in specialty gastroenterology markets. The zero linked job count suggests this is either a niche product requiring targeted recruiting or indicates recent hiring completion; roles would focus on field execution, payer management, and GI specialist engagement.
Worked on SUTAB at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo